SAREUM HOLDINGS PLC

(“Sareum” or “the Company”)

CHK1 Clinical Trial Applications

Sareum, the specialist cancer drug discovery and development business, is pleased to announce that it has received formal confirmation from its co-development partner, the CRT Pioneer Fund, that Clinical Trial Applications for Phase I clinical trials of CCT245737, the CHK1 Programme clinical development candidate drug, are intended to be submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in January 2016. In accordance with the CHK1 co-investment agreement, Sareum will therefore satisfy its next financial contribution, in respect of its 27.5 per cent investment share, of £797,500 by 29 December 2015.

As reported in the Company’s Final Results in October 2015, two clinical trials in cancer patients are planned, one with CCT245737 as a single agent and one in combination with standard-of-care chemotherapy. The funds required for the Company’s financial contribution to these trials will be met from existing cash resources.

Sareum’s CEO, Dr Tim Mitchell, commented: “We are delighted to report this significant step towards these two planned clinical trials with cancer patients, and look forward to reporting further progress in due course.” 

For further information:

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting

020 7220 1666

Hybridan LLP (Co-Broker)

 

Claire Noyce / William Lynne

020 3764 2341/2342

The Communications Portfolio (Media enquiries)

 

Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk 

07785 922 354

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and autoimmune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

Checkpoint Kinase 1 (CHK1) is important in controlling the way many cancer cells respond to DNA damage, which may be a consequence of the cancer itself, or intentionally caused by chemotherapy or radiotherapy. Inhibition of CHK1 affects the ability of the cell to repair this damage and can therefore potentiate the effect of certain chemotherapeutic drugs.  The clinical candidate CHK1 inhibitor, known as CCT245737, could potentially treat a range of cancers including pancreatic, bowel and non-small cell lung cancer (NSCLC) in combination with DNA-damaging chemotherapy drugs and/or radiotherapy. The inhibitor could also potentially treat certain neuroblastoma, lymphoma and acute myeloid leukaemia (AML) types when dosed alone.